Emergent Biosolutions, Inc. (NYSE:EBS) EVP Adam Havey sold 7,885 shares of the company’s stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $39.50, for a total value of $311,457.50. Following the completion of the sale, the executive vice president now owns 33,931 shares in the company, valued at approximately $1,340,274.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Adam Havey also recently made the following trade(s):

  • On Friday, September 8th, Adam Havey sold 7,885 shares of Emergent Biosolutions stock. The shares were sold at an average price of $37.06, for a total value of $292,218.10.

Shares of Emergent Biosolutions, Inc. (NYSE:EBS) opened at 40.45 on Monday. Emergent Biosolutions, Inc. has a 52-week low of $24.47 and a 52-week high of $40.60. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of 25.76 and a beta of 1.26. The company’s 50-day moving average is $36.27 and its 200 day moving average is $32.70.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing the Zacks’ consensus estimate of $0.26 by ($0.13). Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The firm had revenue of $100.77 million for the quarter, compared to analysts’ expectations of $111.57 million. During the same quarter in the previous year, the company posted ($0.05) EPS. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. On average, analysts expect that Emergent Biosolutions, Inc. will post $1.54 earnings per share for the current fiscal year.

WARNING: “Emergent Biosolutions, Inc. (EBS) EVP Sells $311,457.50 in Stock” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/02/emergent-biosolutions-inc-ebs-evp-sells-311457-50-in-stock.html.

A number of large investors have recently made changes to their positions in the stock. Riverhead Capital Management LLC lifted its position in Emergent Biosolutions by 102.8% in the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,542 shares during the period. Ameritas Investment Partners Inc. increased its position in Emergent Biosolutions by 23.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 587 shares during the period. Creative Planning increased its position in Emergent Biosolutions by 1.2% during the 2nd quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 55 shares during the period. Envestnet Asset Management Inc. increased its position in Emergent Biosolutions by 17.3% during the 1st quarter. Envestnet Asset Management Inc. now owns 5,710 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 844 shares during the period. Finally, Laurion Capital Management LP acquired a new position in Emergent Biosolutions during the 2nd quarter worth approximately $214,000. Hedge funds and other institutional investors own 85.35% of the company’s stock.

EBS has been the subject of a number of analyst reports. Wells Fargo & Company reissued an “outperform” rating and issued a $43.00 price target (up from $41.00) on shares of Emergent Biosolutions in a report on Saturday. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Friday, August 25th. Finally, Zacks Investment Research cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $45.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.